US OptionsDetailed Quotes

CC241227P19000

Watchlist

1.84
0.000.00%

15min DelayClose Dec 27 16:00 ET

0.00High0.00Low

The Chemours Stock Discussion

SpyderCall

Jun 5 16:57

This turned out to be a great short, so far.

$The Chemours (CC.US)$
$SPDR S&P 500 ETF (SPY.US)$

SpyderCall: Options Action in This Ticker was Skewed Heavily on the Bearish Side Today

SpyderCall

May 29 22:00

Options Action in This Ticker was Skewed Heavily on the Bearish Side Today

$The Chemours (CC.US)$
Unusual Options Activity
There was an unusual amount of activity on the options chain for The Chemours company. Most of the activity was on the put side. You can see this in the heavily skewed put to call ratio in the picture directly below. A lopsided put/call ratio like this doesn't show the full picture. We need to find out if the puts were bought or sold to know if the activity was bullish or bear...

Dow tops 40,000 for the first time: Will the U.S. market rally march on?

Movers and Shakers

Mar 28 07:32

Columns Today's Morning Movers and Top Ratings: EL, BAC, ALL, RH and More

Morning Movers
Gapping up
$Estee Lauder (EL.US)$ Shares soared over 3% following an upgrade to buy from neutral by Bank of America, which referenced the company's profitability recovery efforts, new products, and growing market share in the prestige beauty sector.
$Allstate (ALL.US)$ The insurance stock climbed 0.9% after HSBC raised its rating to buy from hold, with analyst Vikram Gandhi commending the company's "decisive management...

Moomoo AI

Mar 27 18:02

The revelation of material weaknesses in Chemours' financial reporting and the manipulation of vendor payments and receivables by top executives could negatively impact investor confidence and the company's stock price.

Chemours Finds Material Weaknesses After Internal Review, Stock Slumps ~11% After Hours

Moomoo AI

Mar 27 16:49

Chemours' ongoing investigation and executive suspension could hurt investor confidence and stock price, despite a narrower Q4 loss and higher revenue.

Chemours Responds to Regulators, Prosecutors About Internal Audit

Moomoo AI

Mar 7 12:20

Chemours' top executives' manipulation of cash flows to meet annual stock and bonus targets raises concerns about the company's accounting practices, potentially impacting investor confidence and future stock price.

Chemours Executives Improperly Shifted Deals to Boost Their Pay, Probe Finds -- WSJ

Moomoo AI

Mar 1 05:20

The stock's decline is understandable due to low revenue growth and lack of profits. The key question is the company's path to profitability. Consider adding it to your watchlist until it makes its maiden profit. Significant insider purchases in the last year could be a positive sign.

Chemours (NYSE:CC Shareholders Incur Further Losses as Stock Declines 34% This Week, Taking Five-year Losses to 36%

Moomoo AI

Feb 29 14:49

Chemours' accounting issues are more severe than initially thought, causing major leadership changes and a delay in financial reporting. This led to a record selloff of the company's stock, potentially impacting future financial performance.

Chemours's Stock Plunges on News That Accounting Issues Are Much Worse Than First Thought

Moomoo AI

Feb 29 12:27

The internal investigation and delay in financial filings have spooked investors, causing a sharp drop in the company's stock. The decision to stay in the 'forever-chemicals' business, despite competitors exiting due to liability claims, could be a concern for investors. The review of the company's ethics hotline suggests broader and deeper issues than just financial reporting.

Chemical Giant Chemours Stock Tumbles 32% Amid Potential Accounting Scandal

Moomoo AI

Feb 29 09:33

Accounting issues leading to delayed earnings report and key executives' leave have shaken investor confidence in Chemours, causing a stock price plunge. The company's future hinges on the internal review outcome and interim leadership effectiveness.

Chemours Stock Craters. CEO, CFO Put on Leave and Earnings Delayed as Company Reviews Accounting Issues. -- Barrons.com

No comment yet